120 related articles for article (PubMed ID: 11578812)
1. Serum levels of matrix metalloproteinase 2 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Sheen CC; Chen WJ
Cancer Lett; 2001 Nov; 173(1):79-82. PubMed ID: 11578812
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of transforming growth factor beta1 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Sheen CW; Eng HL; Chen WJ
Arch Surg; 2001 Aug; 136(8):937-40. PubMed ID: 11485532
[TBL] [Abstract][Full Text] [Related]
4. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of tumor necrosis factor in patients with breast cancer.
Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
Breast Cancer Res Treat; 1997 May; 43(3):211-5. PubMed ID: 9150900
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
[TBL] [Abstract][Full Text] [Related]
8. Serum and tissue expression of gelatinase and Twist in breast cancer.
Huang J; Ang L; Liu MQ; Hu HG; Wang J; Zou Q; Zhao Y; Zheng L; Zhao M; Wu ZS
Eur Rev Med Pharmacol Sci; 2014; 18(18):2662-9. PubMed ID: 25317801
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble E-selectin in women with breast cancer.
Sheen-Chen SM; Eng HL; Huang CC; Chen WJ
Br J Surg; 2004 Dec; 91(12):1578-81. PubMed ID: 15386328
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer.
Sheen-Chen SM; Eng HL; Sheen CW; Cheng YF; Chou FF; Chen WJ
Anticancer Res; 1997; 17(4A):2823-6. PubMed ID: 9252723
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women.
Song N; Sung H; Choi JY; Han S; Jeon S; Song M; Lee Y; Park C; Park SK; Lee KM; Yoo KY; Noh DY; Ahn SH; Lee SA; Kang D
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1371-80. PubMed ID: 22634108
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
14. Activity of MMP-2 and MMP-9 in sera of breast cancer patients.
Stankovic S; Konjevic G; Gopcevic K; Jovic V; Inic M; Jurisic V
Pathol Res Pract; 2010 Apr; 206(4):241-7. PubMed ID: 20092959
[TBL] [Abstract][Full Text] [Related]
15. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
Patel S; Sumitra G; Koner BC; Saxena A
Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
[TBL] [Abstract][Full Text] [Related]
16. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of plasma MMP-2 and MMP-9 levels as biomarkers for tumor expression in breast cancer patients in Egypt.
Alrehaili AA; Gharib AF; Karam RA; Alhakami RA; El Sawy WH; Abd Elrahman TM
Mol Biol Rep; 2020 Feb; 47(2):1153-1160. PubMed ID: 31820313
[TBL] [Abstract][Full Text] [Related]
18. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases 2, 7, and 9 in tumors and sera of patients with breast cancer.
Katunina AI; Gershtein ES; Ermilova VD; Tereshkina IV; Nazarenko AY; Tyleuova AA; Dvorova EK; Karabekova ZK; Gritskevich MV; Berezov TT
Bull Exp Biol Med; 2011 Jul; 151(3):359-62. PubMed ID: 22451887
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase-2 in patients with malignant melanoma.
Wollina U; Hipler UC; Knöll B; Graefe T; Kaatz M; Kirsch K
J Cancer Res Clin Oncol; 2001 Oct; 127(10):631-5. PubMed ID: 11599800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
